WuXi PharmaTech has struck a deal with the genomics experts at Foundation Medicine, signing on to offer the company's cancer-decoding services to drug developers in its native China.
CRO giant Icon charted double-digit revenue growth in the third quarter, chugging toward its best-ever year and lifting its earnings projections in the process.
The world's largest CROs are reaping the benefits of two major market trends: Big Pharma is finally getting back to spending big on R&D after some lean years post-downturn, and biotech is enjoying a protracted bit of bullishness that has lined pockets around the industry.
Charles River Laboratories has unveiled a new technology it says can better test for impurities by combining two common methods into a single product, making for a flexible solution.
Observed glitches with Thermo Fisher's popular drug development software have led to concerns that data used to win approvals may have been faulty, and the company is working alongside regulators to figure out just how widespread the issue may be.
DKSH, a well-heeled pharma marketing operation, has reupped with Roche, expanding a long-standing agreement to include more of Asia.
PPD has signed a master service agreement with Swiss biotech Sellas, lending its drug development expertise to the company's efforts to advance a portfolio of treatments.
Provectus Biopharmaceuticals, a biotech that has been stung by regulatory setbacks, has recruited INC Research to audit its data on two drug candidates, tasking the CRO with poring over its documents as it moves into late-stage development.
Catalent has partnered with the Lung Cancer Alliance to survey patients on how they manage the disease and deal with treatment compliance, an effort to highlight unmet needs and match them with new dosage forms.
Covance has joined forces with Novartis to develop new ways to help drug developers quickly integrate and analyze huge swaths of study data.
Parexel International is widening its presence in Nottingham, U.K., tapping local grant funds to consolidate some outposts with plans to grow around its latest acquisition.
North Carolina CRO Clinipace has raised $4 million, and while the company isn't disclosing why it needs the cash, the move follows years of dealmaking and could be a prelude to another buyout.
AstraZeneca is moving forward with a respiratory candidate developed alongside Charles River Laboratories' discovery business, a milestone the CRO says affirms its investments in the space.
Belgian researcher Genae has expanded its U.S. presence with an office in New York City, part of its strategy to capitalize on the North American market for clinical trials.
Early-phase CRO Accelovance has landed a former Pfizer and Otsuka exec to flesh out its efforts in oncology, part of a sweeping growth strategy that has seen the company expand across the U.S.
CRO Chiltern has reached into Singapore for its latest acquisition, buying out an Asian clinical contractor to expand its geographic footprint and therapeutic reach.
In its first acquisition since going public over the summer, Catalent has bought up longtime partner Redwood Bioscience, bringing in proprietary technology for developing antibody-drug conjugates.
Chinese CRO WuXi PharmaTech has bought out XenoBiotic Laboratories, a U.S. contractor focused on early-phase research, expanding its North American presence and broadening its lab-based business.
Parexel International has bought up the U.K.'s ClinIntel, a supply chain software outfit that should fit right in with the CRO's growing technology business.
AstraZeneca is looking to bring more of its IT work in-house, spending money to stand up an Indian hub that will replace much of its contract spend in the field.